Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure

Daniel E. Westerdahl, David H. Chang, Michele A. Hamilton, Mamoo Nakamura, Timothy D. Henry

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Introduction: Over 37 million people worldwide are living with Heart Failure (HF). Advancements in medical therapy have improved mortality primarily by slowing the progression of left ventricular dysfunction and debilitating symptoms. Ultimately, heart transplantation, durable mechanical circulatory support (MCS), or palliative care are the only options for patients with end-stage HF. Regenerative therapies offer an innovative approach, focused on reversing myocardial dysfunction and restoring healthy myocardial tissue. Initial clinical trials using autologous (self-donated) bone marrow mononuclear cells (BMMCs) demonstrated excellent safety, but only modest efficacy. Challenges with autologous stem cells include reduced quality and efficacy with increased patient age. The use of allogeneic mesenchymal precursor cells (MPCs) offers an “off the shelf” therapy, with consistent potency and less variability than autologous cells. Areas covered: Preclinical and initial clinical trials with allogeneic MPCs have been encouraging, providing the support for a large ongoing Phase III trial—DREAM-HF. We provide a comprehensive review of preclinical and clinical data supporting MPCs as a therapeutic option for HF patients. Expert opinion: The current data suggest allogeneic MPCs are a promising therapy for HF patients. The results of DREAM-HF will determine whether allogeneic MPCs can decrease major adverse clinical events (MACE) in advanced HF patients.

Original languageEnglish (US)
Pages (from-to)1163-1169
Number of pages7
JournalExpert opinion on biological therapy
Issue number9
StatePublished - Sep 1 2016

Bibliographical note

Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.


  • Heart failure
  • intramyocardial injection
  • mesenchymal precursor cell
  • mesenchymal progenitor cell
  • myocardial regeneration
  • stem cells
  • therapeutic biologics
  • tissue therapy


Dive into the research topics of 'Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure'. Together they form a unique fingerprint.

Cite this